Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Oxford Investment Partners’ fund of funds ends 2012 up 9% thanks to hedge fund, equity, fixed income exposure

Monday, February 04, 2013

amb
Karl Sternberg
From Precy Dumlao, Opalesque Asia:

The UK-based Oxford Investment Partners Ltd (OXIP)’s OXIP Diversified Fund delivered 1.9% (est.) in Q4-12, bringing the entire year’s gains to 9%, thanks to the fund’s equity, hedge fund and fixed income investments that contributed returns in excess of 10%.

As at 31st December 2012 the Fund (OXIP DF) was estimated at £37m ($58.1m).

OXIP DF's hedge fund portfolio returned 5% p.a. since its May 2006 inception, comparing favourably with the industry average of 1.4% p.a.

Portfolio managers Karl Sternberg and Paul Berriman said in OXIP DF’s Q4 2012 newsletter that the fund’s 2012 profits represent two thirds of the rise in the global equity index, "in line with the proportion of a positive year’s equity returns we aim to capture, and well ahead of inflation." The MSCI ACWI (75% hedged to sterling: OXIP's medium-term benchmark) delivered 2.9% for the quarter and 14% for the year. UK conventional gilts returned 2.7% over twelve months, index-linked bonds -0.3%.

The duo expressed their outlook in the newsletter: "Turning to the future there is so much despondency about the world economy that it is difficult not to be a little heartened. Pessimists predict that monetary policy, the main weapon employed in the US, UK and Europe, is running out of efficaciousness. Our view is that we have yet to see the full benefit of previous efforts and we shall see more t......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for